Shorter treatment with pretomanid for drug-resistant tuberculosis
Part of Infections clinical trials.
This study tests a shorter treatment for drug-resistant tuberculosis (TB) using a medicine called pretomanid. It aims to see if a shorter course of treatment can effectively cure TB that doesn't respond to a standard drug called rifampicin, reducing treatment time for patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old and weigh at least 30 kilograms (about 66 pounds).
- You must have tuberculosis (TB) in your lungs that is resistant to the medicine rifampicin, confirmed by tests in the last 3 months.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use effective birth control during the study and for 3 months after.
- If you are a man who could father a child, you must agree to use condoms or other effective birth control for your partner.
- If you are breastfeeding, you must be willing to stop breastfeeding from the start of the study until 3 months after treatment ends.
- You must be willing to have an HIV test (if positive, you must agree to accept HIV treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
This study tests a shorter-course treatment for tuberculosis (TB) in people 65 and older. It compares a new ultra-short regimen to the usual longer one, using the drugs bedaquiline, linezolid, and pyrazinamide, to see if a shorter treatment is just as effective and safer for older adults.
This study tests a shorter treatment combination (using pretomanid) for people who have both diabetes and TB that is resistant to common drugs. It aims to see if this new short course works well and is safe for this group, potentially reducing treatment time.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This study tests a shorter treatment for a type of TB that is resistant to rifampicin (a common TB medicine) but still sensitive to isoniazid. It aims to see if this shorter regimen is as effective as the current longer one, potentially making treatment less burdensome for patients.
This study tests a 6-month treatment with four oral medicines (bedaquiline, delamanid, linezolid, and levofloxacin) for people whose TB is resistant to rifampin. The goal is to see if this all-pill combination is safe and effective in treating this difficult type of TB.
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.